H. M. E. Hassaneen et al. · Enamines In Heterocyclic Synthesis
1135
3-Ethoxycarbonyl-1-(4-chlorophenyl)-4-(4-nitrophenyl)pyr-
azole (8g)
70 eV): m/z (%) = 276 (55.9) [M+], 247 (100), 230 (50),
111 (57), 75 (38), 51 (19). – C12H10N5OCl (275.72): calcd.
C 52.27, H 3.65, N 25.40; found C 52.30, H 3.62, N 25.35.
Dark yellow crystals, 69% yield, m.p. 177 ◦C. – IR
(KBr): ν 1719 (C=O) cm−1. – 1H NMR (300 MHz,
CDCl3): δ = 1.35 – 1.40 (t, 3H, J = 7 Hz, CH3), 4.34 –
4.45 (q, 2H, J = 7 Hz, CH2), 7.26 – 7.90 (m, 8H, arom-H),
8.04 (s, 1H, pyrazole-5-H). – MS (EI, 70 eV): m/z (%) =
372 (100) [M+], other major fragments: 299 (66), 75 (32),
51 (12). – C18H14N3O4Cl (371.79): calcd. C 58.15, H 3.79,
N 11.30; found C 58.11, H 3.77, N 11.23.
N-[2-(4-Chlorophenyl)-7-oxo-6,7-dihydro-2H-pyrazolo
[3,4-d]pyridazin-4-ylmethyl]acetamide (14)
A solution of 13 (2.76 g, 0.01 mol) in acetic anhy-
dride (20 ml) was refluxed for 3 h. The reaction mixture
was cooled and the solid that separated was collected and
crystallized from dimethylformamide to give 14, (2.15 g,
◦
78%), m.p. 260 C. – IR (KBr): ν 3296 (NH), 3121 (NH),
1709 (C=O) 1691 (C=O) cm−1. – 1H NMR (300 MHz, [D6]-
DMSO) of 14a: δ = 1.91 (s, 3H, CH3CO), 2.61 (s, 2H,
CH2-olefinic), 3.30 (br, 2H, 2NH), 7.70 – 8.07 (m, 4H, arom-
H), 9.20 (s, 1H, pyrazole-H-3) and 1H NMR (300 MHz,
[D6]-DMSO) of 14b: δ = 1.88 (s, 3H, CH3CO), 3.30 (br,
3H, 3NH), 4.44 – 4.46 (d, 2H, CH-olefinic), 7.70 – 8.07 (m,
4H, arom-H), 9.42 (s, 1H, pyrazole-3-H). – MS (EI,
70 eV): m/z (%) = 318 (48.2) [M+], other major fragments:
274 (100), 75 (6), 51 (3). – C14H12N5O2Cl (317.75): calcd.
C 52.91, H 3.80, N 22.04; found C 52.90, H 3.77, N 22.10.
3-(7-Methyl-2-phenyl-2H-pyrazolo[4,3-e]pyridin-5-yl)-1-
phenyl-1H-pyrazol-4-yl-amine (12)
A suspension of nitro compound 8a (1.16 g, 0.005 mol)
and Zn dust (0.01 mol) in methanol (3 ml) was stirred with
◦
hydrazinium monoformate (2 ml) at 20 C. The reaction
mixture was filtered through celite. The organic layer was
evaporated and the residue was triturated with chloroform
where it solidified. The crude product was collected to give
◦
12, (0.59 g, 51%), m.p. 310 C. – IR (KBr): ν 3298, 3363
1
(NH2) cm−1. – Insoluble in common H NMR solvents. –
MS (EI, 70 eV): m/z (%) = 366 (30.3) [M+], other major
fragments: 313 (23), 230 (23), 171 (10), 137 (11), 121 (12),
114 (56), 73 (10), 55 (100). – C22H18N6 (366.38): calcd.
C 72.12, H 4.94, N 22.94; found C 72.07, H 4.90, N 22.92.
4-Aminomethyl-2-(4-chlorophenyl)-7-methyl-2,6-dihydro-
pyrazolo[3,4-d]pyridazine (15)
A mixture of 8c (4.07 g, 0.01 mol) and hydrazine hy-
drate (5 ml, 85%) was refluxed for 5 min. The reaction mix-
ture was left to cool and the solid product was collected
and crystallized from dimethylformamide to give 15, (3.26 g,
4-Aminomethyl-2-(4-chlorophenyl)-2,6-dihydropyr-
azolo[3,4-d]pyridazin-7-one (13)
A mixture of 8d (4.38 g, 0.01 mol) and hydrazine hydrate 80%), m.p. 174 ◦C. – IR (KBr): ν 3337, 3289 (NH2) cm−1
(5 ml, 85%) was refluxed for 5 min. The reaction mixture
was left to cool and the solid product was collected and crys-
.
–
1H NMR (300 MHz, [D6]-DMSO): δ = 1.62 (s, 3H,
CH3CO); 2.50 (s, 2H, CH2-olefinic), 3.92 (br, 2H, NH2),
tallized from dimethylformamide to give 13, (3.50 g, 80%), 7.42 – 8.15 (m, 4H, arom-H), 9.60 (s, 1H, pyrazole-3-H). –
MS (EI, 70 eV): m/z (%) = 274 (7.7) [M+], other major
fragments: 243 (55), 162 (87), 104 (100), 75 (62), 51 (56).
◦
m.p. 299 C. – IR (KBr): ν 3337, 3289 (NH2), 3199 (NH),
1665 (C=O) cm−1 – 1H NMR (300 MHz, [D6]-DMSO): δ =
2.50 (s, 2H, CH2-olefinic), 3.23 (br, 3H, NH, NH2), 7.64 – – C13H12N5Cl (273.75): calcd. C 57.04, H 4.41, N 25.58;
found C 57.09, H 4.39, N 25.50.
8.08 (m, 4H, arom-H), 9.41 (s, 1H, pyrazole-3-H). – MS (EI,
[1] Y. C. Fiamegos, G. A. Pilidis, G. Varvounis, J. Hetero-
cycl. Chem. 38, 1065 (2001).
[6] L. R. Baxendale, S. V. Ley, Bioorg. Med. Chem. Lett.
10, 1983 (2000).
[2] Y. Tominaga, N. Yoshioka, S. Kataoka, N. Aoyama,
T. Masunari, A. Miike, Tetrahedron Lett. 36, 8641
(1995).
[3] L. Infantes, C. Foces-Foces, R. M. Claramunt,
C. Lopez, J. Elguero, J. Heterocycl. Chem. 36, 595
(1999).
[4] T. T. Luebbers, P. P. Angehrn, H. H. Gmuender, S. S.
Herzig, J. J. Kulhanek, Bioorg. Med. Chem. Lett. 10,
821 (2000).
[7] S. D. Dharmpal, L. M. Rogelio, Tetrahedron Lett. 45,
4265 (2004).
[8] B. E. Blass, A. Srivastava, K. R. Coburn, A. L. Faulkner
and W. L. Seibel, Tetrahedron Lett. 44, 3009 (2003).
[9] K. Unverferth, J. Engel, N. Hoefgen, A. Rostock,
R. Guenther, J. Med. Chem. 41, 63 (1998).
[10] K. Harada, S. Nishino, T. Harada, M. Ogami, Jpn.
Kokai, Tokkyo Koho, JP. 294576 (2001); Chem. Ab-
str. 135, 303884p (2001).
[5] M. Tahir, R. H. Gorey, P. Brain, C. N. Nicola, Tetrahe-
dron Lett. 45, 2137 (2004).
[11] H. Braun, U.S. Pat. Appl. US 9044 (2001); Chem. Ab-
str. 135, 126915b (2001).
Brought to you by | University of Sydney
Authenticated
Download Date | 10/25/15 11:56 PM